Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 74 entries
Sorted by: Best Match Show Resources per page
Effect of Web-Based Versus Paper-Based Questionnaires and Follow-Up Strategies on Participation Rates of Dutch Childhood Cancer Survivors: A Randomized Controlled Trial.

JMIR cancer

Kilsdonk E, van Dulmen-den Broeder E, van der Pal HJ, Hollema N, Kremer LC, van den Heuvel-Eibrink MM, van Leeuwen FE, Jaspers MW, van den Berg MH.
PMID: 28410161
JMIR Cancer. 2015 Nov 24;1(2):e11. doi: 10.2196/cancer.3905.

BACKGROUND: Questionnaires are widely used in survey research, especially in cohort studies. However, participation in questionnaire studies has been declining over the past decades. Because high participation rates are needed to limit the risk of selection bias and produce...

Cite
Kilsdonk E, van Dulmen-den Broeder E, van der Pal HJ, et al. Effect of Web-Based Versus Paper-Based Questionnaires and Follow-Up Strategies on Participation Rates of Dutch Childhood Cancer Survivors: A Randomized Controlled Trial. JMIR Cancer. 2015;1(2):e11doi: 10.2196/cancer.3905.
Kilsdonk, E., van Dulmen-den Broeder, E., van der Pal, H. J., Hollema, N., Kremer, L. C., van den Heuvel-Eibrink, M. M., van Leeuwen, F. E., Jaspers, M. W., & van den Berg, M. H. (2015). Effect of Web-Based Versus Paper-Based Questionnaires and Follow-Up Strategies on Participation Rates of Dutch Childhood Cancer Survivors: A Randomized Controlled Trial. JMIR cancer, 1(2), e11. https://doi.org/10.2196/cancer.3905
Kilsdonk, Ellen, et al. "Effect of Web-Based Versus Paper-Based Questionnaires and Follow-Up Strategies on Participation Rates of Dutch Childhood Cancer Survivors: A Randomized Controlled Trial." JMIR cancer vol. 1,2 (2015): e11. doi: https://doi.org/10.2196/cancer.3905
Kilsdonk E, van Dulmen-den Broeder E, van der Pal HJ, Hollema N, Kremer LC, van den Heuvel-Eibrink MM, van Leeuwen FE, Jaspers MW, van den Berg MH. Effect of Web-Based Versus Paper-Based Questionnaires and Follow-Up Strategies on Participation Rates of Dutch Childhood Cancer Survivors: A Randomized Controlled Trial. JMIR Cancer. 2015 Nov 24;1(2):e11. doi: 10.2196/cancer.3905. PMID: 28410161; PMCID: PMC5367669.
Copy Download .nbib Format: NLM
Determinants of impairments in functioning, fatigue, and participation ability in pediatric brain tumor survivors.

Neuro-oncology advances

Verwaaijen EJ, Catsman-Berrevoets CE, Maurice-Stam H, Dessens AB, Waslander R, van den Adel TPL, Pluijm SMF, Reddingius RE, Michiels E, van den Heuvel-Eibrink MM, Hartman A.
PMID: 34988449
Neurooncol Adv. 2021 Nov 03;3(1):vdab161. doi: 10.1093/noajnl/vdab161. eCollection 2021.

BACKGROUND: Pediatric brain tumor survivors (PBTS) experience disease- and treatment-related sequelae. We aimed to investigate the occurrence of participation limitations, impairments in functioning, fatigue, and the association between patient, tumor- and treatment-related factors and these outcomes.METHODS: Children (4-18 years)...

Cite
Verwaaijen EJ, Catsman-Berrevoets CE, Maurice-Stam H, et al. Determinants of impairments in functioning, fatigue, and participation ability in pediatric brain tumor survivors. Neurooncol Adv. 2021;3(1):vdab161doi: 10.1093/noajnl/vdab161.
Verwaaijen, E. J., Catsman-Berrevoets, C. E., Maurice-Stam, H., Dessens, A. B., Waslander, R., van den Adel, T. P. L., Pluijm, S. M. F., Reddingius, R. E., Michiels, E., van den Heuvel-Eibrink, M. M., & Hartman, A. (2021). Determinants of impairments in functioning, fatigue, and participation ability in pediatric brain tumor survivors. Neuro-oncology advances, 3(1), vdab161. https://doi.org/10.1093/noajnl/vdab161
Verwaaijen, Emma J, et al. "Determinants of impairments in functioning, fatigue, and participation ability in pediatric brain tumor survivors." Neuro-oncology advances vol. 3,1 (2021): vdab161. doi: https://doi.org/10.1093/noajnl/vdab161
Verwaaijen EJ, Catsman-Berrevoets CE, Maurice-Stam H, Dessens AB, Waslander R, van den Adel TPL, Pluijm SMF, Reddingius RE, Michiels E, van den Heuvel-Eibrink MM, Hartman A. Determinants of impairments in functioning, fatigue, and participation ability in pediatric brain tumor survivors. Neurooncol Adv. 2021 Nov 03;3(1):vdab161. doi: 10.1093/noajnl/vdab161. eCollection 2021. PMID: 34988449; PMCID: PMC8704380.
Copy Download .nbib Format: NLM
Estimated clinical benefit of combining highly conformal target volumes with Volumetric-Modulated Arc Therapy (VMAT) versus conventional flank irradiation in pediatric renal tumors.

Clinical and translational radiation oncology

Mul J, Seravalli E, Bosman ME, van de Ven CP, Littooij AS, van Grotel M, van den Heuvel-Eibrink MM, Janssens GO.
PMID: 34027140
Clin Transl Radiat Oncol. 2021 May 03;29:20-26. doi: 10.1016/j.ctro.2021.04.007. eCollection 2021 Jul.

BACKGROUND: For decades, Anterior-Posterior/Posterior-Anterior (AP/PA) photon beams were standard-of-care for flank irradiation in children with renal cancer. Recently, highly conformal flank target volumes were defined correcting for postoperative organ shift and intra-fraction motion.By radiotherapy treatment plan comparison, this study...

Cite
Mul J, Seravalli E, Bosman ME, et al. Estimated clinical benefit of combining highly conformal target volumes with Volumetric-Modulated Arc Therapy (VMAT) versus conventional flank irradiation in pediatric renal tumors. Clin Transl Radiat Oncol. 2021;29:20-26doi: 10.1016/j.ctro.2021.04.007.
Mul, J., Seravalli, E., Bosman, M. E., van de Ven, C. P., Littooij, A. S., van Grotel, M., van den Heuvel-Eibrink, M. M., & Janssens, G. O. (2021). Estimated clinical benefit of combining highly conformal target volumes with Volumetric-Modulated Arc Therapy (VMAT) versus conventional flank irradiation in pediatric renal tumors. Clinical and translational radiation oncology, 2920-26. https://doi.org/10.1016/j.ctro.2021.04.007
Mul, Joeri, et al. "Estimated clinical benefit of combining highly conformal target volumes with Volumetric-Modulated Arc Therapy (VMAT) versus conventional flank irradiation in pediatric renal tumors." Clinical and translational radiation oncology vol. 29 (2021): 20-26. doi: https://doi.org/10.1016/j.ctro.2021.04.007
Mul J, Seravalli E, Bosman ME, van de Ven CP, Littooij AS, van Grotel M, van den Heuvel-Eibrink MM, Janssens GO. Estimated clinical benefit of combining highly conformal target volumes with Volumetric-Modulated Arc Therapy (VMAT) versus conventional flank irradiation in pediatric renal tumors. Clin Transl Radiat Oncol. 2021 May 03;29:20-26. doi: 10.1016/j.ctro.2021.04.007. eCollection 2021 Jul. PMID: 34027140; PMCID: PMC8134033.
Copy Download .nbib Format: NLM
Risk factors associated with tinnitus in 2948 Dutch survivors of childhood cancer: a Dutch LATER questionnaire study.

Neuro-oncology advances

Meijer AJM, Fiocco MF, Janssens GO, Clemens E, Tissing WJE, Loonen JJ, van Dulmen-den Broeder E, de Vries ACH, Bresters D, Versluys B, Ronckers CM, Kremer LCM, van der Pal HJ, Neggers SJCMM, van der Heiden-van der Loo M, Stokroos RJ, Hoetink AE, van Grotel M, van den Heuvel-Eibrink MM.
PMID: 33196041
Neurooncol Adv. 2020 Sep 15;2(1):vdaa122. doi: 10.1093/noajnl/vdaa122. eCollection 2020.

BACKGROUND: Tinnitus is a serious late effect of childhood cancer treatment. The aim of this study was to determine the occurrence and risk factors for tinnitus in a national cohort of childhood cancer survivors (CCS).METHODS: Data were collected within...

Cite
Meijer AJM, Fiocco MF, Janssens GO, et al. Risk factors associated with tinnitus in 2948 Dutch survivors of childhood cancer: a Dutch LATER questionnaire study. Neurooncol Adv. 2020;2(1):vdaa122doi: 10.1093/noajnl/vdaa122.
Meijer, A. J. M., Fiocco, M. F., Janssens, G. O., Clemens, E., Tissing, W. J. E., Loonen, J. J., van Dulmen-den Broeder, E., de Vries, A. C. H., Bresters, D., Versluys, B., Ronckers, C. M., Kremer, L. C. M., van der Pal, H. J., Neggers, S. J. C. M. M., van der Heiden-van der Loo, M., Stokroos, R. J., Hoetink, A. E., van Grotel, M., & van den Heuvel-Eibrink, M. M. (2020). Risk factors associated with tinnitus in 2948 Dutch survivors of childhood cancer: a Dutch LATER questionnaire study. Neuro-oncology advances, 2(1), vdaa122. https://doi.org/10.1093/noajnl/vdaa122
Meijer, Annelot J M, et al. "Risk factors associated with tinnitus in 2948 Dutch survivors of childhood cancer: a Dutch LATER questionnaire study." Neuro-oncology advances vol. 2,1 (2020): vdaa122. doi: https://doi.org/10.1093/noajnl/vdaa122
Meijer AJM, Fiocco MF, Janssens GO, Clemens E, Tissing WJE, Loonen JJ, van Dulmen-den Broeder E, de Vries ACH, Bresters D, Versluys B, Ronckers CM, Kremer LCM, van der Pal HJ, Neggers SJCMM, van der Heiden-van der Loo M, Stokroos RJ, Hoetink AE, van Grotel M, van den Heuvel-Eibrink MM. Risk factors associated with tinnitus in 2948 Dutch survivors of childhood cancer: a Dutch LATER questionnaire study. Neurooncol Adv. 2020 Sep 15;2(1):vdaa122. doi: 10.1093/noajnl/vdaa122. eCollection 2020. PMID: 33196041; PMCID: PMC7648591.
Copy Download .nbib Format: NLM
Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset.

Data in brief

Langer T, Clemens E, Broer L, Maier L, Uitterlinden AG, de Vries ACH, van Grotel M, Pluijm SFM, Binder H, Mayer B, von dem Knesebeck A, Byrne J, van Dulmen-den Broeder E, Crocco M, Grabow D, Kaatsch P, Kaiser M, Spix C, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, van der Kooi AF, Kremer LC, Kruseova J, Bielack S, Sorg B, Hecker-Nolting S, Kuehni CE, Ansari M, Kompis M, van der Pal HJ, Parfitt R, Deuster D, Matulat P, Tillmanns A, Tissing WJE, Beck JD, Elsner S, Am Zehnhoff-Dinnesen A, van den Heuvel-Eibrink MM, Zolk O.
PMID: 32939381
Data Brief. 2020 Aug 24;32:106227. doi: 10.1016/j.dib.2020.106227. eCollection 2020 Oct.

Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity. Among other candidate genes, thiopurine methyltransferase (

Cite
Langer T, Clemens E, Broer L, et al. Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data Brief. 2020;32:106227doi: 10.1016/j.dib.2020.106227.
Langer, T., Clemens, E., Broer, L., Maier, L., Uitterlinden, A. G., de Vries, A. C. H., van Grotel, M., Pluijm, S. F. M., Binder, H., Mayer, B., von dem Knesebeck, A., Byrne, J., van Dulmen-den Broeder, E., Crocco, M., Grabow, D., Kaatsch, P., Kaiser, M., Spix, C., Kenborg, L., Winther, J. F., Rechnitzer, C., Hasle, H., Kepak, T., van der Kooi, A. F., Kremer, L. C., Kruseova, J., Bielack, S., Sorg, B., Hecker-Nolting, S., Kuehni, C. E., Ansari, M., Kompis, M., van der Pal, H. J., Parfitt, R., Deuster, D., Matulat, P., Tillmanns, A., Tissing, W. J. E., Beck, J. D., Elsner, S., Am Zehnhoff-Dinnesen, A., van den Heuvel-Eibrink, M. M., Zolk, O. (2020). Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data in brief, 32106227. https://doi.org/10.1016/j.dib.2020.106227
Langer, Thorsten, et al. "Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset." Data in brief vol. 32 (2020): 106227. doi: https://doi.org/10.1016/j.dib.2020.106227
Langer T, Clemens E, Broer L, Maier L, Uitterlinden AG, de Vries ACH, van Grotel M, Pluijm SFM, Binder H, Mayer B, von dem Knesebeck A, Byrne J, van Dulmen-den Broeder E, Crocco M, Grabow D, Kaatsch P, Kaiser M, Spix C, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, van der Kooi AF, Kremer LC, Kruseova J, Bielack S, Sorg B, Hecker-Nolting S, Kuehni CE, Ansari M, Kompis M, van der Pal HJ, Parfitt R, Deuster D, Matulat P, Tillmanns A, Tissing WJE, Beck JD, Elsner S, Am Zehnhoff-Dinnesen A, van den Heuvel-Eibrink MM, Zolk O. Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data Brief. 2020 Aug 24;32:106227. doi: 10.1016/j.dib.2020.106227. eCollection 2020 Oct. PMID: 32939381; PMCID: PMC7477761.
Copy Download .nbib Format: NLM
The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments.

Cancer

Meijer AJM, Li KH, Brooks B, Clemens E, Ross CJ, Rassekh SR, Hoetink AE, van Grotel M, van den Heuvel-Eibrink MM, Carleton BC.
PMID: 34490624
Cancer. 2022 Jan 01;128(1):169-179. doi: 10.1002/cncr.33848. Epub 2021 Sep 07.

BACKGROUND: Ototoxicity is a common adverse event of cisplatin treatment. The authors investigated the development of cisplatin-induced hearing loss (CIHL) over time in children with cancer by age and examined the influence of other clinical characteristics on the course...

Cite
Meijer AJM, Li KH, Brooks B, et al. The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments. Cancer. 2021;128(1):169-179doi: 10.1002/cncr.33848.
Meijer, A. J. M., Li, K. H., Brooks, B., Clemens, E., Ross, C. J., Rassekh, S. R., Hoetink, A. E., van Grotel, M., van den Heuvel-Eibrink, M. M., & Carleton, B. C. (2022). The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments. Cancer, 128(1), 169-179. https://doi.org/10.1002/cncr.33848
Meijer, Annelot J M, et al. "The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments." Cancer vol. 128,1 (2022): 169-179. doi: https://doi.org/10.1002/cncr.33848
Meijer AJM, Li KH, Brooks B, Clemens E, Ross CJ, Rassekh SR, Hoetink AE, van Grotel M, van den Heuvel-Eibrink MM, Carleton BC. The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments. Cancer. 2022 Jan 01;128(1):169-179. doi: 10.1002/cncr.33848. Epub 2021 Sep 07. PMID: 34490624.
Copy Download .nbib Format: NLM
Vitamin D supplementation for children with cancer: A systematic review and consensus recommendations.

Cancer medicine

van Atteveld JE, Verhagen IE, van den Heuvel-Eibrink MM, van Santen HM, van der Sluis IM, Di Iorgi N, Simmons JH, Ward LM, Neggers SJCMM.
PMID: 34100559
Cancer Med. 2021 Jul;10(13):4177-4194. doi: 10.1002/cam4.4013. Epub 2021 Jun 08.

BACKGROUND: Prevalent vitamin D deficiency (VDD) and low bone mineral density (BMD) have led to vitamin D supplementation for children with cancer, regardless vitamin D status. However, it remains unsettled whether this enhances bone strength. We sought to address...

Cite
van Atteveld JE, Verhagen IE, van den Heuvel-Eibrink MM, et al. Vitamin D supplementation for children with cancer: A systematic review and consensus recommendations. Cancer Med. 2021;10(13):4177-4194doi: 10.1002/cam4.4013.
van Atteveld, J. E., Verhagen, I. E., van den Heuvel-Eibrink, M. M., van Santen, H. M., van der Sluis, I. M., Di Iorgi, N., Simmons, J. H., Ward, L. M., & Neggers, S. J. C. M. M. (2021). Vitamin D supplementation for children with cancer: A systematic review and consensus recommendations. Cancer medicine, 10(13), 4177-4194. https://doi.org/10.1002/cam4.4013
van Atteveld, Jenneke E, et al. "Vitamin D supplementation for children with cancer: A systematic review and consensus recommendations." Cancer medicine vol. 10,13 (2021): 4177-4194. doi: https://doi.org/10.1002/cam4.4013
van Atteveld JE, Verhagen IE, van den Heuvel-Eibrink MM, van Santen HM, van der Sluis IM, Di Iorgi N, Simmons JH, Ward LM, Neggers SJCMM. Vitamin D supplementation for children with cancer: A systematic review and consensus recommendations. Cancer Med. 2021 Jul;10(13):4177-4194. doi: 10.1002/cam4.4013. Epub 2021 Jun 08. PMID: 34100559; PMCID: PMC8267124.
Copy Download .nbib Format: NLM
Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors.

Cell reports

Calandrini C, van Hooff SR, Paassen I, Ayyildiz D, Derakhshan S, Dolman MEM, Langenberg KPS, van de Ven M, de Heus C, Liv N, Kool M, de Krijger RR, Tytgat GAM, van den Heuvel-Eibrink MM, Molenaar JJ, Drost J.
PMID: 34433038
Cell Rep. 2021 Aug 24;36(8):109568. doi: 10.1016/j.celrep.2021.109568.

Malignant rhabdoid tumors (MRTs) represent one of the most aggressive childhood malignancies. No effective treatment options are available, and prognosis is, therefore, dismal. Previous studies have demonstrated that tumor organoids capture the heterogeneity of patient tumors and can be...

Cite
Calandrini C, van Hooff SR, Paassen I, et al. Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors. Cell Rep. 2021;36(8):109568doi: 10.1016/j.celrep.2021.109568.
Calandrini, C., van Hooff, S. R., Paassen, I., Ayyildiz, D., Derakhshan, S., Dolman, M. E. M., Langenberg, K. P. S., van de Ven, M., de Heus, C., Liv, N., Kool, M., de Krijger, R. R., Tytgat, G. A. M., van den Heuvel-Eibrink, M. M., Molenaar, J. J., & Drost, J. (2021). Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors. Cell reports, 36(8), 109568. https://doi.org/10.1016/j.celrep.2021.109568
Calandrini, Camilla, et al. "Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors." Cell reports vol. 36,8 (2021): 109568. doi: https://doi.org/10.1016/j.celrep.2021.109568
Calandrini C, van Hooff SR, Paassen I, Ayyildiz D, Derakhshan S, Dolman MEM, Langenberg KPS, van de Ven M, de Heus C, Liv N, Kool M, de Krijger RR, Tytgat GAM, van den Heuvel-Eibrink MM, Molenaar JJ, Drost J. Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors. Cell Rep. 2021 Aug 24;36(8):109568. doi: 10.1016/j.celrep.2021.109568. PMID: 34433038.
Copy Download .nbib Format: NLM
Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review.

JAC-antimicrobial resistance

Diepstraten FA, Hoetink AE, van Grotel M, Huitema ADR, Stokroos RJ, van den Heuvel-Eibrink MM, Meijer AJM.
PMID: 34917943
JAC Antimicrob Resist. 2021 Dec 14;3(4):dlab184. doi: 10.1093/jacamr/dlab184. eCollection 2021 Dec.

BACKGROUND: Ototoxicity has been reported after administration of aminoglycosides and glycopeptides.OBJECTIVES: To identify available evidence for the occurrence and determinants of aminoglycoside- and glycopeptide-related ototoxicity in children.MATERIALS AND METHODS: Systematic electronic literature searches that combined ototoxicity (hearing loss, tinnitus...

Cite
Diepstraten FA, Hoetink AE, van Grotel M, et al. Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review. JAC Antimicrob Resist. 2021;3(4):dlab184doi: 10.1093/jacamr/dlab184.
Diepstraten, F. A., Hoetink, A. E., van Grotel, M., Huitema, A. D. R., Stokroos, R. J., van den Heuvel-Eibrink, M. M., & Meijer, A. J. M. (2021). Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review. JAC-antimicrobial resistance, 3(4), dlab184. https://doi.org/10.1093/jacamr/dlab184
Diepstraten, F A, et al. "Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review." JAC-antimicrobial resistance vol. 3,4 (2021): dlab184. doi: https://doi.org/10.1093/jacamr/dlab184
Diepstraten FA, Hoetink AE, van Grotel M, Huitema ADR, Stokroos RJ, van den Heuvel-Eibrink MM, Meijer AJM. Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review. JAC Antimicrob Resist. 2021 Dec 14;3(4):dlab184. doi: 10.1093/jacamr/dlab184. eCollection 2021 Dec. PMID: 34917943; PMCID: PMC8669239.
Copy Download .nbib Format: NLM
A Validated Risk Prediction Model for Bone Fragility in Children With Acute Lymphoblastic Leukemia.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Verwaaijen EJ, Ma J, de Groot-Kruseman HA, Pieters R, van der Sluis IM, van Atteveld JE, Halton J, Fernandez CV, Hartman A, de Jonge R, Lequin MH, Te Winkel ML, Alos N, Atkinson SA, Barr R, Grant RM, Hay J, Huber AM, Ho J, Jaremko J, Koujok K, Lang B, Matzinger MA, Shenouda N, Rauch F, Rodd C, van den Heuvel-Eibrink MM, Pluijm SMF, Ward LM.
PMID: 34610647
J Bone Miner Res. 2021 Dec;36(12):2290-2299. doi: 10.1002/jbmr.4442. Epub 2021 Oct 05.

Although bone fragility may already be present at diagnosis of pediatric acute lymphoblastic leukemia (ALL), routine performance of dual-energy X-ray absorptiometry (DXA) in every child is not universally feasible. The aim of this study was to develop and validate...

Cite
Verwaaijen EJ, Ma J, de Groot-Kruseman HA, et al. A Validated Risk Prediction Model for Bone Fragility in Children With Acute Lymphoblastic Leukemia. J Bone Miner Res. 2021;36(12):2290-2299doi: 10.1002/jbmr.4442.
Verwaaijen, E. J., Ma, J., de Groot-Kruseman, H. A., Pieters, R., van der Sluis, I. M., van Atteveld, J. E., Halton, J., Fernandez, C. V., Hartman, A., de Jonge, R., Lequin, M. H., Te Winkel, M. L., Alos, N., Atkinson, S. A., Barr, R., Grant, R. M., Hay, J., Huber, A. M., Ho, J., Jaremko, J., Koujok, K., Lang, B., Matzinger, M. A., Shenouda, N., Rauch, F., Rodd, C., van den Heuvel-Eibrink, M. M., Pluijm, S. M. F., Ward, L. M. (2021). A Validated Risk Prediction Model for Bone Fragility in Children With Acute Lymphoblastic Leukemia. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 36(12), 2290-2299. https://doi.org/10.1002/jbmr.4442
Verwaaijen, Emma J, et al. "A Validated Risk Prediction Model for Bone Fragility in Children With Acute Lymphoblastic Leukemia." Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research vol. 36,12 (2021): 2290-2299. doi: https://doi.org/10.1002/jbmr.4442
Verwaaijen EJ, Ma J, de Groot-Kruseman HA, Pieters R, van der Sluis IM, van Atteveld JE, Halton J, Fernandez CV, Hartman A, de Jonge R, Lequin MH, Te Winkel ML, Alos N, Atkinson SA, Barr R, Grant RM, Hay J, Huber AM, Ho J, Jaremko J, Koujok K, Lang B, Matzinger MA, Shenouda N, Rauch F, Rodd C, van den Heuvel-Eibrink MM, Pluijm SMF, Ward LM. A Validated Risk Prediction Model for Bone Fragility in Children With Acute Lymphoblastic Leukemia. J Bone Miner Res. 2021 Dec;36(12):2290-2299. doi: 10.1002/jbmr.4442. Epub 2021 Oct 05. PMID: 34610647.
Copy Download .nbib Format: NLM
Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients.

Cancers

van de Velde ME, Panetta JC, Wilhelm AJ, van den Berg MH, van der Sluis IM, van den Bos C, Abbink FCH, van den Heuvel-Eibrink MM, Segers H, Chantrain C, van der Werff Ten Bosch J, Willems L, Evans WE, Kaspers GL.
PMID: 32635465
Cancers (Basel). 2020 Jul 04;12(7). doi: 10.3390/cancers12071789.

Vincristine (VCR) is frequently used in pediatric oncology and can be administered intravenously through push injections or 1 h infusions. The effects of administration duration on population pharmacokinetics (PK) are unknown. We described PK differences related to administration duration...

Cite
van de Velde ME, Panetta JC, Wilhelm AJ, et al. Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients. Cancers (Basel). 2020;12(7)doi: 10.3390/cancers12071789.
van de Velde, M. E., Panetta, J. C., Wilhelm, A. J., van den Berg, M. H., van der Sluis, I. M., van den Bos, C., Abbink, F. C. H., van den Heuvel-Eibrink, M. M., Segers, H., Chantrain, C., van der Werff Ten Bosch, J., Willems, L., Evans, W. E., & Kaspers, G. L. (2020). Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients. Cancers, 12(7), . https://doi.org/10.3390/cancers12071789
van de Velde, Mirjam Esther, et al. "Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients." Cancers vol. 12,7 (2020). doi: https://doi.org/10.3390/cancers12071789
van de Velde ME, Panetta JC, Wilhelm AJ, van den Berg MH, van der Sluis IM, van den Bos C, Abbink FCH, van den Heuvel-Eibrink MM, Segers H, Chantrain C, van der Werff Ten Bosch J, Willems L, Evans WE, Kaspers GL. Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients. Cancers (Basel). 2020 Jul 04;12(7). doi: 10.3390/cancers12071789. PMID: 32635465; PMCID: PMC7407622.
Copy Download .nbib Format: NLM
Characteristics and Outcome of Children with Renal Cell Carcinoma: A Narrative Review.

Cancers

van der Beek JN, Geller JI, de Krijger RR, Graf N, Pritchard-Jones K, Drost J, Verschuur AC, Murphy D, Ray S, Spreafico F, Dzhuma K, Littooij AS, Selle B, Tytgat GAM, van den Heuvel-Eibrink MM.
PMID: 32635225
Cancers (Basel). 2020 Jul 03;12(7). doi: 10.3390/cancers12071776.

Pediatric renal cell carcinoma (RCC) is a rare type of kidney cancer, most commonly occurring in teenagers and young adolescents. Few relatively large series of pediatric RCC have been reported. Knowledge of clinical characteristics, outcome and treatment strategies are...

Cite
van der Beek JN, Geller JI, de Krijger RR, et al. Characteristics and Outcome of Children with Renal Cell Carcinoma: A Narrative Review. Cancers (Basel). 2020;12(7)doi: 10.3390/cancers12071776.
van der Beek, J. N., Geller, J. I., de Krijger, R. R., Graf, N., Pritchard-Jones, K., Drost, J., Verschuur, A. C., Murphy, D., Ray, S., Spreafico, F., Dzhuma, K., Littooij, A. S., Selle, B., Tytgat, G. A. M., & van den Heuvel-Eibrink, M. M. (2020). Characteristics and Outcome of Children with Renal Cell Carcinoma: A Narrative Review. Cancers, 12(7), . https://doi.org/10.3390/cancers12071776
van der Beek, Justine N, et al. "Characteristics and Outcome of Children with Renal Cell Carcinoma: A Narrative Review." Cancers vol. 12,7 (2020). doi: https://doi.org/10.3390/cancers12071776
van der Beek JN, Geller JI, de Krijger RR, Graf N, Pritchard-Jones K, Drost J, Verschuur AC, Murphy D, Ray S, Spreafico F, Dzhuma K, Littooij AS, Selle B, Tytgat GAM, van den Heuvel-Eibrink MM. Characteristics and Outcome of Children with Renal Cell Carcinoma: A Narrative Review. Cancers (Basel). 2020 Jul 03;12(7). doi: 10.3390/cancers12071776. PMID: 32635225; PMCID: PMC7407101.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 74 entries